drugset / Trial / NCT01773785
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the effectiveness of SPI-1620 in combination with docetaxel in patients with advanced biliary cancer.
Timeline
- Start
- 2013-04
- Primary completion
- 2015-09
- Completion
- 2015-09
Outcome
Outcome not reported
Stopped: “The study completed the first phase and did not meet efficacy end point to enter into the randomized phase.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SOVATELITIDE | Peptide | 11 ug/m2 | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |